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Dimethylfumarate Induces Immunosuppression
via Glutathione Depletion and Subsequent
Induction of Heme Oxygenase 1
Joachim C.U. Lehmann1,3, Joanna J. Listopad1, Christine U. Rentzsch1, Frederik H. Igney1, Arne von Bonin1,
Hartwig H. Hennekes2, Khusru Asadullah1 and Wolf-Dietrich F. Docke1
A mixture of different fumaric acid esters (FAE) is established for systemic therapy of psoriasis, a frequent
inflammatory skin disease. The main active compound of FAE, however, has not been identified so far, and the
mechanisms of activity are only partially understood. We analyzed the impact of FAE on in vitro immune
function and aimed to gain knowledge about the mode of action. Dimethylfumarate (DMF) and diethylfumarate
(DEF), but not fumaric acid, methylhydrogenfumarate and ethylhydrogenfumarate, exhibited potent depression
of inflammatory cytokine secretion (e.g., tumor necrosis factora, IL-12, and IFNg) in activated human peripheral
blood mononuclear cells. Moreover, solely DMF and DEF inhibited alloreactive T-cell proliferation in mixed
leukocyte reaction. Interestingly, these immunosuppressive effects were accompanied by the strong induction
of the anti-inflammatory stress protein heme oxygenase 1 (HO-1). Supplementation with exogenous glutathione
(GSH), which is known to bind DMF, prevented both HO-1 induction as well as the anti-inflammatory effects of
DMF. Moreover, inhibition of HO-1 activity restored the diminished IL-12 and IFNg production after FAE
treatment. These results suggest that DMF acts as active compound within the FAE mixture and at least partially
mediates its immunomodulatory activity by the induction of the anti-inflammatory stress protein HO-1 ascribed
to the functional depletion of reduced GSH.
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INTRODUCTION
Since the German biochemist Schweckendieck (1959)
reported the successful treatment of psoriasis with fumaric
acid esters (FAE), therapeutic approaches with fumaric ester
derivatives have been under discussion (Nieboer et al., 1989;
Mrowietz et al., 1999; Sebok and Schneider, 2000). During
the last decades, effectiveness of systemic therapy with
mixtures of different FAE as well as their side effects have
been comprehensively demonstrated in clinical trials (Bayard
et al., 1987; Nieboer et al., 1990; Nugteren-Huying et al.,
1990). In 1994 a mixture consisting of dimethylfumarate
(DMF) and three salts of ethylhydrogenfumarate (EHF) was
registered for oral therapy of severe psoriasis in Germany
under the brand name Fumaderms, and registration is
pending in many European countries (Zhu and Mrowietz,
2001). Today Fumaderms is the most frequently prescribed
drug for systemic treatment of psoriasis in Germany,
even though a high frequency of adverse gastrointestinal
effects and flushing are observed mostly during the first
months of treatment. However, data about the long-term use
of fumarates did not reveal an increased risk of infections,
malignancies, or any other long-term adverse effects (Kol-
bach and Nieboer, 1992; Altmeyer et al., 1994; Thio et al.,
1995; Mrowietz et al., 1998; Hoefnagel et al., 2003).
Despite the high number of investigations performed
to elucidate the principles of FAE treatment, neither the
active compound nor the molecular basis of action have
been identified so far. DMF, the main ingredient of the FAE
mixture, is rapidly metabolized to methylhydrogenfumarate
(MHF), which was therefore considered to be the active
compound (Nibbering et al., 1993). Different investigators
have shown that MHF induces selectively TH2 cytokines (de
Jong et al., 1996) and inhibits the production of inflammatory
mediators as well as the proliferation of different immune
cells (Nibbering et al., 1997). These findings are of particular
interest, considering the well-established role of immune
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cells and their proinflammatory type 1 cytokine production
pattern in the pathophysiology of psoriasis (Asadullah et al.,
2002; Nickoloff and Nestle, 2004), leading to the assumption
that the antipsoriatic activity of FAE is mediated by immune
deviation. Furthermore, a recent report demonstrated the
potential of MHF to inhibit graft rejection in a rat kidney
transplant model (Lehmann et al., 2002).
Even though it is postulated that DMF (half-life
T1/2¼12 minutes) is rapidly degraded to MHF (Mrowietz
et al., 1999), other groups proposed that DMF is clinically
most efficacious. So it has been shown that DMF inhibits the
production of TH1 cytokines and enhances IL-10 production
in keratinocytes (Ockenfels et al., 1998; Sebok et al., 1998).
Additionally, it has been demonstrated that DMF inhibits
chemokine secretion by keratinocytes and peripheral
blood mononuclear cells (PBMCs) (Stoof et al., 2001) as
well as the expression of cytokine-induced adhesion mole-
cules by endothelial cells and keratinocytes (Sebok et al.,
1994; Vandermeeren et al., 1997). Interestingly, it has been
shown that both DMF and MHF impair the differentiation
of monocyte-derived dendritic cells (Zhu and Mrowietz,
2001). Very little is known, however, about the mechanisms
mediating the immunomodulatory effects of FAE. A couple of
reports suggest that FAE inhibits the NF-kappaB pathway,
showing evidence that DMF prevents the nuclear entry of
tumor necrosis factor (TNF)-induced NF-kappaB/p65 in
human endothelial cells (Loewe et al., 2001, 2002; Vander-
meeren et al., 2001).
Heme oxygenase 1 (HO-1), also known as heat-shock
protein 32, is a potent anti-inflammatory intracellular
mediator. It was first identified in the liver of rats (Maines
et al., 1986) and subsequently found to be rather ubiquitously
expressed in many organs as well as in cells of the immune
system (McFaul and McGrath, 1987; Ewing et al., 1992; Lee
et al., 1996; Ishii et al., 1999). Noting that HO-1 is induced
by exposure to various forms of oxidative and other stressors,
this protein is recognized to provide cellular protection
by inhibiting several immune effector functions (Woo et al.,
1998; Elbirt and Bonkovsky, 1999). Furthermore it has
been demonstrated that targeted gene transfer or pharmaco-
logical enhancement of HO-1 expression provide protective
effects upon brain, liver, kidney, or lung injury as well as
gastrointestinal diseases and transplantation (Immenschuh
and Ramadori, 2000; Guo et al., 2001; Katori et al.,
2002). Effects of FAE upon HO-1 expression have not been
investigated so far. As FAE are known to bind to GSH (Held
et al., 1988) and GSH depletion is suggested to trigger HO-1
induction (Ewing and Maines, 1993), this might represent a
potential mechanism of FAE action.
Here we show that DMF as well as diethylfumarate (DEF),
but not MHF, EHF, and fumaric acid (FA), are potent
immunosuppressants in vitro, suggesting that out of the
mixture of FAE used in the clinic DMF is most likely to be
the main active ingredient. Furthermore the data suggest that
the immunosuppressive effects of DMF and DEF are mediated
by the functional depletion of reduced glutathione (GSH),
leading to a strong induction of the anti-inflammatory stress
protein HO-1. The depletion of GSH by FAE might explain
the discrepancy between the short half-life of DMF and its
proposed clinical efficacy. The covalent bond formation of
FAE with intracellular GSH might stabilize DMF preventing
the rapid degradation to MHF. Remarkably, inhibition of
HO-1 activity was able to prevent the inhibitory effect of
DMF and DEF on IL-12 and IFNg production in primary
human immune cells.
RESULTS
Solely DMF and DEF suppress the secretion of
inflammatory cytokines
To reveal the active compounds of FAEs we investigated the
impact of FA itself, MHF, EHF, DMF, and DEF upon cytokine
secretion in human PBMC as well as in separated monocytes
and T cells. EHF and DMF are ingredients of Fumaderms. FA
was added to the study as the substance backbone, MHF as
the rapid metabolite of DMF (Litjens et al., 2004b), and
DEF as a substance very similar to DMF (DEF has two ethyl-
groups instead of two methyl-groups bound to the fumarate
backbone). Analyzing the effects on cytokine secretion
after PBMC stimulation with high doses of lipopolysaccharide
(LPS)/IFNg, targeting monocytes, (Figure 1a) or the lectin
phytohemagglutinin (PHA), stimulating monocytes and lym-
phocytes, (Figure 1c) we found that only the diesters
DMF and DEF were effective in the inhibition of the secretion
of a wide range of cytokines. Remarkably, the secretion
of relevant cytokines for the initiation of inflammatory
reactions like IL-1b, -6, -12p70, TNFa, and IFNg was
drastically inhibited by DMF and DEF. We observed also a
strong inhibition of IL-10 secretion by DMF and DEF. In
contrast the secretion of IL-2 and -4 was not significantly
affected in PHA-stimulated PBMC (Figure 1c).
The diminished expression of the monocytic cytokines
TNFa, IL-12p70, and -10 after DMF or DEF treatment was
confirmed in monocytes isolated from PBMC (Figure 1b).
Isolated T cells activated with immobilized aCD3/aCD28 in
the presence of DMF or DEF showed the same drastic
drop of IFNg and IL-10 secretion, but in contrast to the PHA-
activated PBMCs revealed a strong decrease also in IL-2
and -4 production (Figure 1d). Additionally, T cells activated
with immobilized aCD3/aCD28 in the presence of DMF or
DEF displayed a drop in IL-5 production as well (Figure 1d),
whereas PBMC activated with PHA displayed no detectable
IL-5 production (data not shown). Most effects observed with
DMF and DEF were first seen at concentrations between 3
and 10 mM being almost complete at 30 mM. The other FAE,
FA, MHF, and EHF, did not exhibit any significant effects on
cytokine secretion.
Solely DMF and DEF inhibit lymphocyte proliferation
To address the influence of the different FAEs on T cell-
mediated immunity, mixed leukocyte reactions (MLR)
with allogeneic PBMCs were performed. Solely DMF and
DEF clearly diminished the alloreactive proliferation of
lymphocytes whereas FA, MHF, and EHF had no influence.
The decrease of proliferation was first observed at concentra-
tions of 30 mM, being almost complete at 100mM (Figure 2a).
The suppressed proliferation is not due to diminished IL-2
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levels, as the IL-2 secretion during MLR was even rather
enhanced by higher concentrations of DMF and DEF
(Figure 2b). Using a mitogenic proliferation assay with
PHA stimulation, we found similar results (data not shown)
confirming that only DMF and DEF inhibit lymphocyte
proliferation.
DMF and DEF strongly increase HO-1 expression
As it is known that HO-1 is a potent inhibitor of cellular
immune effector functions (Woo et al., 1998), we investi-
gated by quantitative real-time RT-PCR whether the
anti-inflammatory effects induced by DMF and DEF are
selectively associated with increased levels of HO-1 mes-
senger RNA (mRNA) expression.
In fact, the 4-hour treatment of PBMCs with the
immunosuppressive active diesters, DMF and DEF, yielded
a strong upregulation of HO-1 mRNA in PBMC, whereas FA
and the monoesters MHF and EHF did not increase the HO-1
expression levels (Figure 3a). The effect of DMF and DEF
appeared to be dose-dependent, as higher HO-1 mRNA
expression levels were found after treatment with 50 mM of the
diesters (DMF 13-fold, DEF 9-fold increase vs control) in
comparison to 25 mM treatment (DMF 4-fold, DEF 3-fold
increase). Real-time PCR analyses of the kinetics of
DMF effects on HO-1 mRNA expression in PBMCs yielded
an induction of HO-1 mRNA expression starting at 2 hours
of treatment (9-fold), an expression peak at 4 hours (almost
14-fold), and falling values at 6 hours (6-fold) and 8 hours
(2-fold) (Figure 3b).
In order to specify the cell population in PBMC that
upregulates HO-1 expression upon treatment with FA diesters
we analyzed the effects of DMF in separated monocytes and
T cells (Figure 3c). DMF revealed a strong dose-dependent
induction of HO-1 mRNA expression in monocytes. At the
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Figure 1. DMF and DEF suppress inflammatory cytokine secretion. The influence of FAE on cytokine secretion of primary human peripheral blood immune cells
was determined after 24hours culture with different stimuli and FAEs. Cytokine concentrations are shown as percentage (mean7SD) of levels in control cultures.
(a) LPS/IFNg (1mg/ml, 10ng/ml) induced cytokine secretion in human PBMC (n¼6). Concentrations in control culture: TNFa 34.179.2 ng/ml, IL-12p70
28.673.7pg/ml. (b) LPS/IFNg (1mg/ml, 10 ng/ml) induced cytokine secretion in separated human monocytes (n¼ 6). Concentrations in control culture: TNFa
28.973.1ng/ml, IL-10 0.670.4 ng/ml, and IL-12p40 4.771.4 ng/ml. (c) PHA (100mg/ml) induced cytokine secretion in human PBMC (n¼ 6). Concentrations in
control culture: IFNg 3.770.3 ng/ml, IL-1b 9.771.2 ng/ml, IL-2 2.870.9 ng/ml, IL-4 126723pg/ml, IL-6 53.4712.3ng/ml, and IL-10 2.870.8 ng/ml. (d) Anti-CD3/
ant-CD28 induced cytokine secretion in purified human T cells (n¼ 5–6). IFNg 1.570.8 ng/ml, IL-2 26.878.9 ng/ml, IL-4 0.370.4 ng/ml, IL-5 0.470.5 ng/ml,
and IL-10 2.271.2 ng/ml. **Po0.01 and *Po0.05 versus control culture (100%).
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highest concentration of 50mM DMF a more than 10-fold
increase in HO-1 mRNA expression compared to the control
was observed. Additionally, DMF augmented the HO-1
mRNA expression level in T cells as well (up to the 10-fold),
although the overall expression of HO-1 mRNA levels in
monocytes was much higher compared to those in T cells
(almost 250-fold higher). As observed in the primary cells
DMF and DEF induced HO-1 in the monocytic cell line THP-1
in a dose-dependent manner; at the maximum concentrations
of 60 mM we observed a 5-fold induction of HO-1 (data not
shown).
It has been reported that DMF covalently binds GSH (Held
et al., 1988), and additionally it has been shown that GSH
depletion leads to anti-inflammatory effects evoked by the
induction of HO-1 (Ewing and Maines, 1993; Horikawa
et al., 2002). Therefore we hypothesized that the induction
of the anti-inflammatory stress protein HO-1 by DMF as
well as DEF is based on GSH depletion. To test this, PBMCs
were incubated with 25 mM DMF with or without substitution
of high amounts (1 mM) of exogenous reduced glutathione
monoethyl-glycyl-ester (GSH-OEt). In contrast to GSH,
GSH-OEt is efficiently transported into many cell types and
intracellularly hydrolyzed to GSH (Wellner et al., 1984;
Anderson et al., 1985; Deneke and Fanburg, 1989). HO-1
mRNA expression was analyzed after 4 hours.
The incubation with DMF increased the expression levels
of HO-1 mRNA in PBMC. Remarkably, this induction of
HO-1 mRNA by DMF was almost completely prevented by
substitution with high amounts of exogenous GSH-OEt
(Figure 3d). This suggests that the induction of HO-1 by FA
diesters might be induced via GSH depletion. To further
support these findings PBMCs were incubated with 1,3-bis-2-
chloroethyl-1-nitrosourea, an irreversible inhibitor of the
GSH reductase, leading to GSH depletion and therefore a
strong upregulation of HO-1 mRNA (Yoshida et al., 1987).
Treatment of PBMC with 100mM 1,3-bis-2-chloroethyl-1-
nitrosourea resulted in a similar 4-fold increase of HO-1
mRNA expression as it was observed with 25 mM DMF and
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Figure 2. DMF and DEF inhibit lymphocyte proliferation in MLR. The
influence of FAE on alloreactive lymphocyte proliferation was determined in
triplicated cultures in MLR. Responder and allogeneic stimulator PBMCs were
cultured for 5 days in the presence of the different FAE at the indicated
concentrations. (a) Lymphocyte proliferation was analyzed by 3H-thymidine
incorporation for additional 6 hours. (b) IL-2 concentrations in the
supernatants were determined before the addition of 3H-thymidine. Values
from five independent experiments are shown as percentage (mean7SD) of
those in control cultures (100%): 3H-thymidine incorporation
6,32971,230 c.p.m., IL-2 concentration 111.7727.4 pg/ml. **Po0.01 and
*Po0.05 versus control culture (100%).
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Figure 3. DMF induces HO-1 expression. Expression of the
anti-inflammatory stress protein HO-1 was analyzed by quantitative real-time
RT-PCR in peripheral blood immune cells treated with FAE. (a) HO-1 mRNA
expression was determined in PBMC cultured with the different FAE for
4 hours. (b) Kinetics of HO-1 mRNA expression was determined in PBMC
treated with 25 mM DMF for the indicated times. (c) To clarify the responsible
cell type for HO-1 induction, HO-1 mRNA expression was determined after
4 hours of culture of negatively separated monocytes and T cells with different
concentrations of DMF. (d) To establish GSH depletion as mechanism of
DMF-induced HO-1 induction, HO-1 mRNA expression was determined in
PBMC treated with 25 mM DMF with or without addition of 1 mM GSH-OEt.
1,3-Bis-2-chloroethyl-1-nitrosourea (GSH depletor) and CoPP (cobaltic
protoporphyrin IX, GSH-independent HO-1 inducer) at the indicated
concentrations served as controls. Values are shown as mean7SD from
three independent experiments.
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was solely dependent on GSH depletion. In contrast, the
more than 30-fold HO-1 induction by cobaltic protoporphyr-
in IX, besides other pathways a GSH-independent inducer of
HO-1 (Rublevskaya and Maines, 1994), was not influenced
by substitution with exogenous GSH-OEt.
Substitution of reduced GSH abolishes the inhibition of
inflammatory cytokine secretion and alloreactive lymphocyte
proliferation by DMF and DEF
To estimate whether GSH depletion has functional relevance
for the immunosuppressive effects of the FA diesters, we
tested whether GSH-OEt substitution prevents the inhibition
of proinflammatory cytokine secretion and alloreactive
lymphocyte proliferation by DMF and DEF. Remarkably,
GSH-OEt substitution of PBMC stimulated with LPS/IFNg or
PHA almost completely abolished the inhibitory effect of
DMF, respectively DEF, on TNFa, IL-12p70, IFNg, IL-1b, -6,
and -10 secretion (Figure 4a).
Moreover, substitution of GSH-OEt also completely
prevented the suppression of alloreactive lymphocyte pro-
liferation by DMF and DEF (Figure 4b). In contrast, addition
of exogenous GSH-OEt had no effect on the inhibition of
alloreactive T-cell response induced by treatment with the
GSH-independent HO-1 inducer cobaltic protoporphyrin IX
(Figure 4b).
HO-1 antagonization counteracts inhibition of IL-12
and IFNc secretion by DMF and DEF
Next we addressed the question whether the inhibition
of cytokine production by DMF and DEF is a direct
consequence of the observed HO-1 induction.
As DMF and DEF induces the expression of HO-1 in the
monocytic cell line THP-1 up to 5-fold, we used HO-1-
specific small interfering RNA (siRNA) and observed up to
95% reduction of HO-1 mRNA expression in THP1 cells
(Figure 5a). Whereas HO-1 knockdown had no effect on the
inhibition of LPS (100 ng/ml) induced TNFa secretion by DMF
and DEF (data not shown), we observed a clear loss (up to
85%) of the inhibitory effect of the FA diesters on IL-12p40
secretion in THP1 cells (Figure 5b).
The effect of HO-1 enzyme inhibition on the anti-
inflammatory effect of DMF and DEF was tested in LPS-
and PHA-stimulated PBMC. Inhibition of HO-1 activity by tin
protoporphyrin IX (SnPPIX) almost completely restored the
inhibitory effect of DMF and DEF on IL-12p40 secretion but
had no effect on TNFa inhibition (Figure 5c). Given that IL-12
is a main inducer of IFNg in lymphocytes, we tested the effect
of HO-1 inhibition on the suppression of IFNg secretion in
PHA-stimulated PBMCs. In fact, we observed a widely
prevention of the inhibitory effects of DMF and DEF on IFNg
secretion by additional treatment with the HO-1 inhibitor
SnPPIX (Figure 5d). Taken together these data imply that
HO-1 induction is involved in the inhibition of at least IL-12
and IFNg secretion by DMF and DEF.
Superinduction of TNFa secretion at low doses of DMF and DEF
During the initial low-dose phase of clinical therapy
FAE frequently induce gastrointestinal side effects and flush.
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Figure 4. Substitution of GSH abolishes the inhibitory effects of DMF on
inflammatory cytokine secretion and alloreactive lymphocyte proliferation.
Exogenous GSH-OEt substitution was used to verify whether GSH depletion is
responsible for the immunosuppressive in vitro effects of DMF. (a, b) PBMCs
were stimulated with LPS/IFNg (1 mg/ml, 10 ng/ml) or PHA (100 mg/ml) in the
presence of (a) DMF and (b) DEF with or without addition of 1 mM GSH-OEt.
Cytokine concentrations in the supernatants were determined after 24 hours).
Values from two independent experiments (one experiment for IL-6) are given
as percentage (mean7SD) of the levels in control cultures (100%) for LPS
stimulation (TNFa 51.0714.8 ng/ml, IL-10 3.071.4 ng/ml, and IL-12p70
473.57175.7 pg/ml) and PHA stimulation (IFNg 4.170.4 ng/ml, IL-1b
7.970.7 ng/ml, and IL-6 49.1 ng/ml). (c, d) Five-day MLR with responder and
allogeneic stimulator PBMC was performed in the presence of (c) DMF and
(d) CoPP, respectively, with or without 0.5 mM GSH-OEt substitution.
Lymphocyte proliferation was assessed by 3H-thymidine incorporation during
the last 6 hours. Values from five independent experiments are shown as
percentage (mean7SD) from those in control cultures (100%): 3H-thymidine
incorporation 30,780710,714 c.p.m. **Po0.01 and *Po0.05 versus control
culture (100%).
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It has been postulated that these adverse effects result from
an increased TNFa release by monocytes/macrophages
(Asadullah et al., 1997). In fact, the PDE 4 inhibitor
pentoxifylline, which is known to suppress TNFa production
in vitro and in vivo, ameliorated the side effect induction in
initial Fumaderm therapy in psoriasis (Zabel et al., 1993;
Friedrich et al., 2001). Astonishing, in PBMC from a few
probands (two out of seven) we observed a super-induction
of LPS/IFNg-induced TNFa secretion by low-dose treatment
with DMF and DEF (2–10mM) (Figure 6a). As this in vitro
phenomenon may represent an equivalent for the inflammatory
side effects frequently observed in FAE-treated patients we tested
whether it is dependent on GSH depletion and, this way,
intrinsic to the assumed mechanism of active FAE. Remarkably,
the observed superinduction of TNFa is completely prevented by
GSH-OEt substitution (Figure 6b).
DISCUSSION
Whereas the efficacy of FAE therapy in psoriasis is well
established, there is still a need to identify the active
ingredient within the mixture of Fumaderms, which has
been successfully used in the clinic for years. Additionally,
only limited knowledge exists regarding the mode of action.
Studies over the last decade provide evidence that FAE are
potent immune modulators showing remarkable effects
on T cells, monocytes, dendritic cells, endothelial cells,
fibroblasts, and keratinocytes (de Jong et al., 1996; Asadullah
et al., 1997; Hoxtermann et al., 1998; Stoof et al., 2001;
Vandermeeren et al., 2001; Zhu and Mrowietz, 2001; Loewe
et al., 2002). Significant limitations of the majority of
previous studies are the lack of systematic inquiries of several
FAE compounds in direct comparison and the use of at least
in part very high concentrations, which are not likely to be
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Figure 5. HO-1 antagonization counteracts inhibition of IL-12 and IFNc secretion by DMF and DEF. (a) Kinetics of HO-1 knockdown by siRNA in
unstimulated and LPS (100 ng/ml) stimulated THP-1 cells (one representative out of two independent experiments). (b) Effect of HO-1 knockdown on inhibition
of IL-12p40 secretion by DMF and DEF in LPS (100 ng/ml) stimulated THP-1 cells after 24 hours culture. IL-12p40 concentrations are given as percentage
(mean7SD of two independent experiments) of the levels in control culture (100%): IL-12p40 6057669 pg/ml. (c) Effect of HO-1 inhibition by SnPPIX (50 mM)
on inhibition of IL-12p40 and TNFa secretion by DMF and DEF in LPS (100 ng/ml) stimulated PBMC after 6 hours culture. Cytokine concentrations are given as
mean7SD of six independent experiments. **Po0.01 versus similarly treated cultures without SnPPIX. (d) Effect of HO-1 inhibition by SnPPIX (50 mM) on
inhibition of IFNg secretion by DMF and DEF in PHA (100 mM) stimulated PBMC after 6 hours culture. IFNg concentrations are given as mean7SD of six
independent experiments. **Po0.01 versus cultures without SnPPIX.
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relevant for the in vivo situation (Mrowietz et al., 1999;
Litjens et al., 2003, 2004a).
In this study, we examined the effects of different FAE,
including all compounds being present in the approved
therapeuticum Fumaderms, over a wide dose range in
several assays in primary human immune cells. It turned
out that only DMF and DEF potently suppress lymphokine
and monokine secretion as well as alloreactive and mitogenic
lymphoproliferative responses. These observations consoli-
date several other publications indicating that DMF is the
active compound among FAE. For instance it has been
shown that DMF inhibits the secretion of a variety of
cytokines and chemokines by activated human PBMC
(Ockenfels et al., 1998; Stoof et al., 2001). In contrast to
some publications (Nibbering et al., 1993; de Jong et al.,
1996) MHF did not diminish the secretion of inflammatory
cytokines in our study.
Furthermore we observed no induction of TH2 cytokines
as IL-4 and -5 after DMF or DEF treatment contradicting
reports by other groups (de Jong et al., 1996; Ockenfels et al.,
1998; Litjens et al., 2003). Whereas FAE did not significantly
affect IL-4 levels in PHA-stimulated PBMC, the secretion
of IL-4 and -5 was even strongly inhibited by DMF and
DEF in aCD3/aCD28-stimulated isolated T cells. A compar-
able pattern was observed for IL-2 secretion. The discrepancy
between the strong inhibition of IL-4, -5, and -2 secretion by
DMF and DEF in stimulated T cells and the failing
suppression or even slightly enhancing effect in mitogen-
stimulated PBMC indicates that other cell types interfere with
the effect of FAE on these cytokines. In contrast, IFNg and
IL-10 secretion was suppressed in stimulated T cells and PBMCs.
Interestingly, the reduced alloreactive T-cell proliferation
after DMF and DEF treatment was also not accompanied with
reduced IL-2 levels. Concluding from similar results after
HO-1 induction Woo et al. (1998) suggested an IL-2 indepen-
dent cell arrest in the G0/G1 phase. The rather increased IL-2
levels in MLR might also reflect a lower consumption of the
initially produced IL-2 owing to the decreased proliferation.
Though contradictory to some in vitro reports, our results
are concordant with clinical data showing no beneficial
effect of MHF monotherapy (Nieboer et al., 1989) as well as
observations made in psoriasis patients showing a reduction
of TH1 but no concomitant increase of TH2 cytokines in the
course of successful Fumaderms therapy (Litjens et al.,
2003). Additionally, FAE-treated psoriasis patients revealed
reduced numbers of lymphocytes and activated CD25þ
T cells in the blood (Hoxtermann et al., 1998) indicating the
in vivo relevance of our observations as well.
Several surveys have been conducted to elucidate the
mode of action of FAE in the treatment of psoriasis. However,
the molecular mechanism for the effects observed with FAE
remains still obscure. The data presented here suggest a
strong anti-inflammatory mechanism that might initiate the
therapeutic effect observed in psoriasis treatment with FAE.
Our findings indicate that the anti-inflammatory and im-
munosuppressive effects of DMF and DEF on human primary
immune cells are initiated by the functional depletion of
intracellular GSH. The intracellular GSH depletion then leads
to the induction of the anti-inflammatory active stress protein
HO-1, which at least in part is responsible for the diminished
secretion of inflammatory cytokines. It has to be mentioned
that an initial GSH depletion by DMF, triggering HO-1
induction, is followed by a counter-regulatory GSH increase
(Dethlefsen et al., 1988; Nelson et al., 1999). Remarkably,
the induced increased HO-1 activity may also contribute to
this secondary antioxidative response (Liu et al., 2004).
The small thiol GSH, found in the millimolar range in
cells, is known to be involved in the cellular defense against
the exposure to toxic agents. Furthermore, the cellular
response to stress often involves changes in the content of
GSH which is first consumed in reactions protecting the
cell (Dickinson and Forman, 2002). Interestingly, GSH
depletion has been shown to have protective effects in
inflammation. It ameliorates tissue injury in models of renal
ischemia and reperfusion (Horikawa et al., 2002) and may
also provide benefits under neurodegenerative conditions
(Ewing and Maines, 1993). The importance of the intracel-
lular redox system for the specific immune system is
supported by data from Nathens et al. (1998) who described
a prolonged survival of renal allografts by GSH depletion.
Several groups have linked these anti-inflammatory and
immunosuppressive effects of GSH depletion to the induction
of the potent anti-inflammatory stress protein HO-1 (Yoshida
et al., 1987; Immenschuh and Ramadori, 2000; Horikawa
et al., 2002).
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Figure 6. Substitution of GSH abolishes the casual stimulatory effect of
low-dose DMF on TNFa secretion. (a) In some experiments monocytic
endotoxin-induced TNFa secretion was increased by treatment with low
concentrations of DMF. PBMCs were stimulated with high doses of LPS
(1 mg/ml) and IFNg (10 ng/ml) in the presence of DMF at the indicated
concentrations. Cytokine concentrations were determined in pooled
supernatants of duplicated cultures after 24 hours. Data from one
representative out of two independent experiments are shown. This effect may
be an equivalent to the transient increase in TNFa plasma levels, which
have been observed in psoriasis patients during the clinical treatment with
FAE. (b) Data from the same experiments are shown for treatment with
10mM DMF or DEF with or without substitution of 1 mM GSH-OEt. Data
from two independent experiments are shown as percentage (mean7SD)
of values in the control cultures (100%): TNFa 33.074.7 ng/ml.
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In our study, the substitution of GSH by GSH-OEt resulted
in a complete abrogation of HO-1 induction as well as the
inhibition of cytokine secretion and alloreactive T-cell
proliferation by FA diesters. Moreover, the inhibition of
HO-1 activity by either siRNA or SnPPIX reconstituted
the suppressed IL-12p40 and IFNg secretion by DMF and
DEF treatment. These data indicate that a HO-1 increase
triggered by GSH depletion in FAE treatment may lead
to a diminished expression of IL-12 and -23, two cytokines
with profound proinflammatory activity sharing the IL-12p40
subunit (Oppmann et al., 2000). As these cytokines are
upregulated in lesional psoriatic skin (Lee et al., 2004;
Piskin et al., 2006; Tada et al., 2006) and their neutraliza-
tion by anti-p40 antibodies has been successful in a
clinical study in psoriasis patients (Kauffman et al., 2004),
the HO-1 induction in antigen-presenting cells leading to p40
suppression might be a major step for the therapeutic impact
of FAE in psoriasis.
In our study, the strongest induction of HO-1 was
observed in monocytes suggesting that down-modulation
of antigen-presenting cell function might be a prominent
immunological consequence of FAE treatment. It is
known that the redox state of antigen-presenting cells has
great impact upon the TH1/TH2 balance in immunological
responses. Whereas antigen-presenting cell with elevated
intracellular GSH give rise to an augmented IFNg production,
reduced intracellular GSH levels lead to a diminished
immunostimulatory capacity (Peterson et al., 1998; Murata
et al., 2002). Supplementary, Kuppner et al. (2003) demon-
strated an impaired allostimulatory capacity of human
monocyte-derived dendritic cells after intracellular GSH
depletion with 4-hydroxyifosfamide. In concordance with
the proposed mechanism that HO-1 induction triggered by
GSH depletion mediates immunosuppressive effects of FAE, it
has been shown that either DMF itself (Zhu and Mrowietz,
2001) or the induction of HO-1 (Chauveau et al., 2005)
inhibit the maturation and function of dendritic cells.
Even though we suggest that the beneficial effects of FAE
in psoriasis are at least in part owing to the induction of
HO-1, Hanselmann et al. (2001) reported that HO-1 is already
increased in the skin of patients suffering from psoriasis. This is
not surprising, as HO-1 is a stress response enzyme that is
induced by stimuli associated with oxidative stress and
inflammation (Wiesel et al., 2000), but it points out that FAE
treatment might persuade a superinduction of HO-1 in the skin
of psoriasis patients. Interestingly, a quite similar mechanism as
suggested for the FA diesters might apply for anthralin, the
oldest topical therapy for psoriasis, which also reduces the
intracellular GSH levels (Perchellet et al., 1986), as well as for
curcumin, a natural anti-inflammatory compound derived from
Curcuma longa which had already being used as a systemic
therapy for psoriasis patients (Shishodia et al., 2005). It induces
GSH depletion and oxidative stress and shows strong anti-
inflammatory activity by induction of HO-1 (Heng et al., 2000;
Strasser et al., 2005).
Taken together these observations indicate that HO-1
induction triggered by GSH depletion may be one causative
mechanism of the anti-inflammatory and immunosuppressive
effects of FAE in type 1 cytokine-mediated immune patho-
logy. This finding seems to be very promising, as HO-1 has
been associated with anti-inflammatory responses in several
autoimmune models for rheumatoid arthritis, asthma, inflam-
matory bowel disease, and experimental autoimmune en-
cephalitis (Guo et al., 2001; Kitada et al., 2001; Maines,
2002; Hildebrandt et al., 2003). In contrast, HO-1 knockout
mice as well as humans deficient in HO-1 develop
progressive chronic inflammation and show a reduced
cellular resistance to oxidative stress (Yachie et al., 1999;
Wiesel et al., 2000). Moreover, Woo et al. (1998) demon-
strated that overexpression of HO-1 leads to a decreased
alloreactive lymphoproliferative response and a prolongation
of allograft survival in mice.
Surprisingly, the mechanism of GSH depletion might not
only apply to the anti-inflammatory and immunosuppressive
effects of FAE but also for major side effects. The induction of
TNFa by FAEs, which was postulated to be responsible for
side effects like flush at low doses of initial Fumaderms
treatment in psoriasis patients (Kolbach and Nieboer, 1992;
Asadullah et al., 1997; Friedrich et al., 2001; Hoefnagel
et al., 2003), was additionally prevented by GSH substitution
in our in vitro study. It has been reported that inhibition of
GSH can lead to an increased TNFa production (Peristeris
et al., 1992). In the initial phase of FAE therapy (low doses of
FAE) the level of GSH depletion may trigger TNFa production
but may be not sufficient to induce a stable HO-1 expression
counteracting the initial inflammatory stimulus.
Despite the difficulties of detecting DMF after oral uptake
(Werdenberg, 2003 No. 113; Litjens et al., 2004a) excluding
a direct comparison of in vitro and in vivo DMF levels, one
could hypothesize that the dose range for TNFa super-
induction in our experiments might mirror the therapeutic
DMF concentration at the beginning of Fumaderms treat-
ment. Psoriasis patients start with a daily dose of FAE
including 30 mg of DMF which in the course of treatment
rises up to more then 1,100 mg of DMF daily (Hoxtermann
et al., 1998; Balasubramaniam et al., 2004). The frequent
inflammatory side effects are only observed in the beginning
of the treatment and vanish with time and increasing doses of
Fumaderms (Kolbach and Nieboer, 1992; Hoefnagel et al.,
2003; Mrowietz and Asadullah, 2005). Taken together, it is
possible that the side effects associated with the initial
treatment may be intrinsic to the mechanism of FAE therapy.
Although further experimental proof has to be generated, the
data presented here discovers the induction of HO-1 expression
as a novel and central anti-inflammatory mechanism that may
have major importance in immune therapy with FAE. More-
over, the data suggest that the anti-inflammatory activity is
triggered by the intervention of DMF in the cellular redox
system. Further appraisal of this novel pathway for the treatment
of psoriasis will be an interesting and challenging task.
MATERIALS AND METHODS
Compounds, antibodies, and sorting reagents
FA and the FAEs MHF, EHF, DMF, and DEF were obtained from
Sigma-Aldrich/Fluka (Taufkirchen, Germany) or synthesized at the
Medical Chemistry at Schering AG (Berlin, Germany). PHA, LPS
842 Journal of Investigative Dermatology (2007), Volume 127
JCU Lehmann et al.
DMF Acts as a Potent Immunosuppressive Agent
from Escherichia coli 0127 B8, GSH-OEt, mitomycin C, and 1,3-bis-
2-chloroethyl-1-nitrosourea were purchased from Sigma-Aldrich/
Fluka (Taufkirchen, Germany) and recombinant human IFNg
from Boehringer Ingelheim (Ingelheim, Germany). 1,3-Bis-2-chlor-
oethyl-1-nitrosourea, cobaltic protoporphyrin IX and SnPPIX were
obtained from Frontier Scientific (Carnforth, UK). aCD14, aCD3,
and aCD28 were purchased from BD Pharmingen (Heidelberg,
Germany) and all microbeads supplied by Miltenyi Biotec (Bergisch-
Gladbach, Germany).
Cell purification and culture conditions
Human PBMCs were obtained from healthy donors with their
consent under institutional approval and included adherence to the
Declaration of Helsinki Principles. After density gradient centrifuga-
tion (Histopaque-1077, Sigma) and two washing steps with
phosphate-buffered saline the PBMCs were resuspended in cell
culture medium. T cells and monocytes were prepared from PBMCs
by negative separation using depletion Kits and MACS separation
(Miltenyi). Flowcytometry revealed that negatively separated CD3þ
T cells and CD14þ monocytes had a purity of 495%. Cell cultures
were carried out in VLE Rosewell Park Memorial Institute medium
1640 (BioChrom AG, Berlin, Germany) supplemented with 50 U/ml
penicillin/streptomycin and 10% fetal calf serum (both GibcoBRL,
Karlsruhe, Germany) at 371C, 5% CO2.
Cytokine detection in culture supernatants
To investigate the influence of FAE on cytokine production, human
PBMC, isolated T cells, or monocytes were seeded at a density of
1 106 cells/ml in round-bottomed 96-well plates and stimulated with
either PHA (100mg/ml), LPS (1mg/ml) plus IFNg (10 ng/ml), or coated
aCD3/aCD28 (10mg/ml each). FA derivatives were dissolved in
absolute ethanol or DMSO and added at the beginning of stimulation
to the cultures. The final concentration of ethanol or DMSO in the
medium did not exceed 0.4% and vehicle controls with the maximal
concentration were carried along with all experiments. The viability of
cells was not influenced at all investigated dosages as determined by
trypan blue staining (data not shown). All samples were set up as
doublets. After 24 hours culture supernatants were collected, doublets
were pooled and shock frozen at 801C for storage. Cytokine
detection in supernatants was performed using commercial immu-
noassay systems: IFNg, IL-1b, -2, -4, -5, -6, and -10 in cultures
stimulated with PHA were determined with Multiplex Antibody Bead
Kits for Luminex (Biosource, Nivelles, Belgium). The detection of IL-
12p70 in supernatants of LPS/IFNg stimulated cultures was performed
with ELISA plates obtained from R&D (Wiesbaden, Germany). TNFa
detection in supernatants of LPS/IFNg-stimulated cultures was carried
out with TAG- and biotin-labeled aTNFa mAbs (R&D) using IGEN
technology (Oxfordshire, UK); IL-2 in the supernatants (pooled triplets)
of MLRs was determined by ELISA from R&D. The following detection
limits apply: IL-12p70: 0.6 pg/ml; IL-12p40, TNFa: 10 pg/ml; IL-1b, -4
and -6: 20 pg/ml; IL-2, -10 and IFNg: 30 pg/ml; and IL-5: 80 pg/ml.
MLR
PBMCs from two healthy donors were isolated. The cells from one
donor were treated with mitomycin C (25 mg/ml, 371C, 25 minutes).
Afterwards these stimulator PBMCs were mixed with untreated
responder PBMC from the second donor at a ratio of 2:1. This
mixture of stimulator and responder cells was cultured at a
concentration of 6 105 cells/ml as triplets in round-bottomed 96
wells with the addition of either FA, MHF, EHF, DMF, or DEF (1, 3,
10, 30, and 100 mM) for 5 days. Six hours before culture termination
small aliquots from the culture supernatants were taken (for the
subsequent detection of secreted IL-2) and 3H-thymidine was added
to the remaining cultures. Finally, the cells were harvested on glass
fiber filters, and the incorporated radioactivity in each well was
determined by liquid scintillation counting.
Quantitative gene expression analysis
PBMC, T cells, and monocytes (1 106 cells/ml) were cultured under
the influence of 5, 10, 25, or 50mM FA, MHF, EHF, DMF, or DEF in six-
well plates. Total cellular RNA was prepared and mRNA was reversed
transcribed and analyzed by real-time TaqMan PCR in triplicate
as described previously (Gruenberg et al., 2001). HO-1 mRNA
expression data are given as fold expression of that of the housekeeping
gene hypoxanthine phosphoribosyltransferase-1. The sequences and
concentrations of primers and 6-carboxy-fluorescein/6-carboxy-
tetramethyl-rhodamine double-labeled probes were as follows:
HO-1: forward: 50-GAAGAGGCCAAGACTGCGTTC-30 50 nM
reverse: 50-TGGTCCTTGGTGTCATGGGT-30 300 nM probe: FAM-
50-TGCTCAACATCCAGCTCTTTGAGGAGTTG-30-TAMRA 250 nM
HPRT-1 forward: 50-AGTCTGGCTTATATCCAACACTTCG-30 300 nM
reverse: 50-GACTTTGCTTTCCTTGGTCAGG-30 300 nM probe: FAM
50-TTTCACCAGCAAGCTTGCGACCTTGA-30-TAMRA 250 nM.
HO-1 inhibition and siRNA knockdown
To investigate the role of the FAE-induced increased HO-1
expression for the inhibition of cytokine production by FAE we
either inhibited HO-1 function with SnPPIX or knocked down HO-1
expression with siRNA.
For the first set of experiments primary human PBMCs were
seeded at a density of 1 106 cells/ml in round-bottomed 96-well
plates and stimulated with LPS (100 ng/ml) together with the
indicated concentrations of DMF or DEF (dissolved in DMSO) and
50 mM SnPPIX for 6 hours. Cytokine concentrations were determined
from pooled supernatants of duplicated cultures. The final concen-
tration of DMSO in the medium was 0.3% and vehicle controls were
carried along with all experiments.
In the second set of experiments, monocytic THP-1 cells were
electroporated with either control siRNA (Lamin A/C) or HO-1-
specific siRNA obtained from Cenix (Dresden, Germany) and seeded
at a density of 1 106 cells/ml in round-bottomed 96-well plates.
Twenty hours after transfection the cells were stimulated with LPS
(100 ng/ml) with the addition of 30 or 60 mM DMF, respectively DEF,
as indicated. Cytokine concentrations were determined from pooled
supernatants of duplicated cultures after 24 hours. The final
concentration of DMSO in the medium was 0.3% and vehicle
controls were carried along with all experiments.
Statistics
Statistical significance was determined with the Student’s t-test for
two-tailed distribution with unequal variance. Differences were
considered statistically significant with Po0.05 and highly signifi-
cant with Po0.01.
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